ClinicalTrials.gg
CompletedNCT00423449Updated Feb 4, 2016Results posted

Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)

A Phase 1 interventional study of vorinostat and Gemcitabine in Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-02-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.

Enrollment
4th of 19
61 · median 21
Started
2007
with 4 others
Phase 1
11 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
6 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 1, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →

Where they have run

About vorinostat

Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung as a file.
02

Study summary

This is a clinical trial to determine the safety and tolerability of MK0683 in combination with gemcitabine and cisplatin and/or carboplatin.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Advanced Stage IIIB/IV Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must have a -confirmed or locally advanced non-small cell lung cancer that has not been previously treated with systemic chemotherapy or has received non-platinum and non-gemcitabine based or adjuvant chemotherapy if the last dose was at least 6 months prior to study enrollment

Exclusion criteria

Exclusion Criteria:

  • Patient who has had chemotherapy, radiotherapy, or biological therapy prior to entering the study, except for or neoadjuvant chemotherapy, as allowed for treatment of a tumor
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Vorinostat + Gemcitabine + Platinum-based agent

    Drug: vorinostat · Drug: Gemcitabine · Drug: Platinum-based agent

Interventions

  • Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days

  • Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle

  • DrugPlatinum-based agent

    Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin

    DLT = any Common Terminology Criteria for Adverse Events Grade 3/4 drug related non-hematologic toxicity EXCEPT Grade 3 nausea/vomiting responsive to therapy, Grade 3 Fatigue responsive to management, transient electrolyte disorders that were corrected, any Grade 4 drug related hematologic toxicity EXCEPT lymphopenia/neutropenia, unless the neutropenia was febrile and/or was an infection requiring treatment, OR Any Grade 4 neutropenia lasting \>=7 days, failure of absolute neutrophil count or platelets to recover, or any drug-related AE that led to a dose reduction of \>=1 study drugs.

    Time frame: every 21 days (every cycle), up to 126 days (6 cycles)

  2. Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease

    Maximum tolerated dose (MTD) was defined as the highest dose level in which fewer than 2 patients among the first 6 enrolled experience a DLT (as defined in Outcome Measure 1) during the first cycle of treatment. The MTD was 400 mg for up to 10 days in 21-day cycles.

    Time frame: every 21 days (every cycle), up to 126 days (6 cycles)

Secondary outcomes

  1. Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)

    An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).

    Time frame: every 21 days (every cycle), up to 126 days (6 cycles)

  2. Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)

    An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).

    Time frame: every 21 days (every cycle), up to 126 days (6 cycles)

07

Results

Posted Aug 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneVorinostat 300 7/21+ Gemcitabine 1000 + CisplatinVorinostat 300 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 10/21+ Gemcitabine 1250 + CisplatinVorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin
Started4617277
Completed12250
Not completed3415227
Withdrew: Clinical adverse event10182
Withdrew: Death10211
Withdrew: Progressive disease138114
Withdrew: Laboratory adverse event01200
Withdrew: Other00010
Withdrew: Protocol violation00210

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin

DLT = any Common Terminology Criteria for Adverse Events Grade 3/4 drug related non-hematologic toxicity EXCEPT Grade 3 nausea/vomiting responsive to therapy, Grade 3 Fatigue responsive to management, transient electrolyte disorders that were corrected, any Grade 4 drug related hematologic toxicity EXCEPT lymphopenia/neutropenia, unless the neutropenia was febrile and/or was an infection requiring treatment, OR Any Grade 4 neutropenia lasting \>=7 days, failure of absolute neutrophil count or platelets to recover, or any drug-related AE that led to a dose reduction of \>=1 study drugs.

Time frame:
every 21 days (every cycle), up to 126 days (6 cycles)
Reported as:
Number · Participants
Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin
ParticipantsVorinostat 300 7/21+ Gemcitabine 1000 + CisplatinVorinostat 300 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 10/21+ Gemcitabine 1250 + CisplatinVorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin
Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or Carboplatin01001
SecondaryNumber of Participants With Clinical Adverse Experiences (Safety and Tolerability)

An adverse experience (AE) was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).

Time frame:
every 21 days (every cycle), up to 126 days (6 cycles)
Reported as:
Number · Participants
Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)
ParticipantsVorinostat 300 7/21+ Gemcitabine 1000 + CisplatinVorinostat 300 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 10/21+ Gemcitabine 1250 + CisplatinVorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin
Number of Participants With Clinical Adverse Experiences (Safety and Tolerability)4617277
SecondaryNumber of Participants With Laboratory Adverse Experiences (Safety and Tolerability)

An adverse experience was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the sponsor's product, whether or not considered related to the use of the product. Any worsening (any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the sponsor's product, was also an adverse experience. The AEs could have been any grade from 1 to 5 in severity (mild, moderate, severe, life-threatening, death, respectively).

Time frame:
every 21 days (every cycle), up to 126 days (6 cycles)
Reported as:
Number · Participants
Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)
ParticipantsVorinostat 300 7/21+ Gemcitabine 1000 + CisplatinVorinostat 300 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 7/21+ Gemcitabine 1250 + CisplatinVorinostat 400 10/21+ Gemcitabine 1250 + CisplatinVorinostat 400 14/21+ Gemcitabine 1250 + Cisplatin
Number of Participants With Laboratory Adverse Experiences (Safety and Tolerability)247132
PrimaryMaximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease

Maximum tolerated dose (MTD) was defined as the highest dose level in which fewer than 2 patients among the first 6 enrolled experience a DLT (as defined in Outcome Measure 1) during the first cycle of treatment. The MTD was 400 mg for up to 10 days in 21-day cycles.

Time frame:
every 21 days (every cycle), up to 126 days (6 cycles)
Reported as:
Number · mg
Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease
mgAll Participants
Maximum Tolerated Dose of Vorinostat Administered in Combination With Standard Doses of Gemcitabine Plus Either Cisplatin or Carboplatin in Patients With Advanced Stage Non-Small Cell Lung Cancer Who Have Not Received Chemotherapy for Advanced Disease400

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + Cisplatin—3/4 (75%)4/4 (100%)
MK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin—4/6 (66.7%)6/6 (100%)
MK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin—10/18 (55.6%)17/18 (94.4%)
MK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin—18/27 (66.7%)27/27 (100%)
MK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin—4/7 (57.1%)7/7 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventMK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + CisplatinMK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin
ThrombocytopeniaBlood and lymphatic system disorders2/40/60/184/272/7
Chest painGeneral disorders0/42/60/180/270/7
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/42/61/182/271/7
Venous thrombosisVascular disorders0/42/60/180/271/7
AnaemiaBlood and lymphatic system disorders1/40/60/180/271/7
Disease progressionGeneral disorders1/40/62/183/270/7
PyrexiaGeneral disorders1/40/63/180/270/7
Accidental overdoseInjury, poisoning and procedural complications1/40/60/180/270/7
HaemoptysisRespiratory, thoracic and mediastinal disorders1/40/61/181/270/7
Back painMusculoskeletal and connective tissue disorders0/41/60/180/270/7
Most frequent other events
Showing 10 of 148
Most frequent other events
EventMK-0683 300 mg x 7d/21d + Gemcitabine 1000 mg/m^2 + CisplatinMK-0683 300 mg 7d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 7d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 10d/21d + Gemcitabine 1250 mg/m^2 + CisplatinMK-0683 400 mg 14d/21d + Gemcitabine 1250 mg/m^2 + Cisplatin
AnaemiaBlood and lymphatic system disorders4/46/611/1823/274/7
ThrombocytopeniaBlood and lymphatic system disorders3/46/610/1818/275/7
AstheniaGeneral disorders4/46/612/1822/275/7
NauseaGastrointestinal disorders1/45/611/1819/274/7
PyrexiaGeneral disorders3/42/62/186/271/7
NeutropeniaBlood and lymphatic system disorders2/44/612/1815/275/7
ConstipationGastrointestinal disorders2/42/68/189/275/7
VomitingGastrointestinal disorders1/44/67/1813/275/7
Decreased appetiteMetabolism and nutrition disorders2/42/68/1816/275/7
LeukopeniaBlood and lymphatic system disorders1/42/66/189/274/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean56.7 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female17
Male44
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2007
First posted
Jan 18, 2007
Start
Mar 2007
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Results first posted
Aug 2, 2011
Last update
Feb 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00423449
Responsible party
Sponsor
First posted
Jan 18, 2007
Start date
Mar 2007
Primary completion
Apr 2010
Completion
Apr 2010
Results posted
Aug 2, 2011
Last update
Feb 4, 2016

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vorinostat · Gemcitabine

Start the discussion